Related Experiment Video
Updated: Apr 21, 2026
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
Injection site ischemia and inflammation after intravitreal bevacizumab
Nikolaos D Georgakarakos1, Paul Sullivan, Jonathan Dowler
1From the *Institute of Ophthalmology, University College London, London, United Kingdom; and †Moorfields Eye Hospital, London, United Kingdom.
Background:
Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) used in the treatment of a variety of ocular conditions. It is known to exert an inhibitory effect on new vessels but has not previously been documented to affect mature vascular beds.
Methods:
The authors present an uncommon side effect of intravitreal bevacizumab, consisting of inflammation and transient nonperfusion of conjunctival, episcleral, and scleral vessels surrounding the injection site.
Results:
Possible mechanisms of this complication, including ischemia and inflammation, are considered.
Conclusion:
The possibility of this complication should be recognized by clinicians treating patients with intravitreal bevacizumab, and measures should be taken to limit drug reflux at the injection site.
